Literature DB >> 19457654

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

Miriam Koopman1, Sabine Venderbosch, Harm van Tinteren, Marjolijn J Ligtenberg, Iris Nagtegaal, Johan H Van Krieken, Cornelis J Punt.   

Abstract

We have tested several biomarkers [dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), thymidylate synthase (TS) and excision cross-complementing gene (ERCC1)] for their prognostic and predictive value in relation to the outcome of chemotherapy in tumour tissues of 556 advanced colorectal cancer (ACC) patients who were randomised between sequential treatment and combination treatment in the CApecitabine, IRinotecan, Oxaliplatin (CAIRO) study. DPD expression showed a statistically significant predictive value for combination treatment with capecitabine plus irinotecan with low versus high values resulting in an improved median progression-free survival (PFS) and median overall survival (OS) of 8.9 (95% confidence interval (CI) 8.3-9.9) versus 7.2 months (95% CI 6.5-8.1, p=0.006), and 21.5 months (95% CI 17.9-26.5) versus 16.9 months (95% CI 13.0-19.1, p=0.04), respectively. In the overall patient population a high OPRT expression in stromal cells was a favourable prognostic parameter for OS, with 21.5 months (95% CI 17.9-27.3) versus 17.2 months (95% CI 15.1-18.6, p=0.036), respectively. A similar effect was observed for PFS. In a multivariate analysis that included known prognostic factors these results remained significant and also showed that a high OPRT expression in tumour cells was an unfavourable prognostic parameter for PFS and OS. In conclusion, in this largest study on capecitabine with or without irinotecan to date we found a predictive value of DPD expression. Our results on the prognostic value of OPRT expression warrant further studies on the role of stromal cells in the outcome of treatments. The divergent results of ours and previous studies underscore the complexity of these biomarkers and currently prevent the routine use of these markers in daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457654     DOI: 10.1016/j.ejca.2009.04.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  33 in total

1.  Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis.

Authors:  Xingrong Lu; Jie Pan; Shaotang Li; Songfei Shen; Pan Chi; Huiming Lin; Ying Huang; Zhongbin Xu; Shenghui Huang
Journal:  Cancer Biother Radiopharm       Date:  2013-05-30       Impact factor: 3.099

Review 2.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 3.  Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.

Authors:  Nicole E Lopez; Carrie Y Peterson
Journal:  Clin Colon Rectal Surg       Date:  2016-09

4.  Frequent intragenic rearrangements of DPYD in colorectal tumours.

Authors:  A B P van Kuilenburg; M-C Etienne-Grimaldi; A Mahamat; J Meijer; P Laurent-Puig; S Olschwang; M-P Gaub; R C M Hennekam; D Benchimol; S Houry; C Letoublon; F-N Gilly; D Pezet; T Andre; J-L Faucheron; A Abderrahim-Ferkoune; R Vijzelaar; B Pradere; G Milano
Journal:  Pharmacogenomics J       Date:  2014-10-28       Impact factor: 3.550

Review 5.  Biomarker use in colorectal cancer therapy.

Authors:  Robin K Kelley; Grace Wang; Alan P Venook
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

Review 6.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.

Authors:  Sing Yu Moorcraft; Elizabeth C Smyth; David Cunningham
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

8.  Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan.

Authors:  Cornelia Meisenberg; Duncan C Gilbert; Anthony Chalmers; Vikki Haley; Simon Gollins; Simon E Ward; Sherif F El-Khamisy
Journal:  Mol Cancer Ther       Date:  2014-12-18       Impact factor: 6.261

Review 9.  How to select the optimal treatment for first line metastatic colorectal cancer.

Authors:  Alexander Stein; Carsten Bokemeyer
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test.

Authors:  Takumi Ochiai; Kazuhiko Nishimura; Tomoo Watanabe; Masayuki Kitajima; Akinori Nakatani; Takashi Inou; Marie Washio; Naoki Sakuyama; Tsuyoshi Sato; Kenji Kishine; Takanori Ochi; Satoshi Okubo; Shunji Futagawa; Satomi Mashiko; Isao Nagaoka
Journal:  Oncol Lett       Date:  2012-07-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.